ClinicalTrials.gg
CompletedNCT04657302Updated Jan 19, 2024

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 1 interventional study of Obinutuzumab and Glofitamab in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-19.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Lymphoma by Hoffmann-La Roche — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma · Hoffmann-La Roche.

Enrollment
13th of 15
30 · median 96
Started
2021
the only one that year
Phase 1
4 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 1, and was the 14th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 17 studies in Lymphoma by Hoffmann-La Roche is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics, safety, tolerability, and efficacy of glofitamab as a single agent following a fixed single dose of obinutuzumab in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed DLBCL
  • Participants must have or failed to respond to at least two lines of prior systemic therapy (including at least one prior regimen containing anthracycline, and at least one containing an anti-CD20-directed therapy)
  • Participants must have : at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension; or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension
  • (ECOG) Performance Status of 1 or 1
  • Adverse events from prior anti-cancer therapy must have resolved to Grade \</=1
  • Adequate liver, hematological, and renal function
  • Negative serum pregnancy test within 7 days prior to study treatment in women of
  • Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use as defined by the protocol, and agree to refrain from donating eggs during the treatment period and for at least 18 months after the final dose of obinutuzumab, 2 months after the final dose of glofitamab, and 3 months after the final dose of tocilizumab (if applicable)
  • Men must agree to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol, and agree to refrain from donating sperm during the treatment period and for at least 3 months after the final dose of obinutuzumab, 4 months after the final dose of glofitamab, and 2 months after the final dose of tocilizumab (if applicable)
  • Reside in the People's Republic of China

Exclusion criteria

Exclusion Criteria:

  • Richter's transformation
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection within 4 weeks prior to first study treatment
  • Suspected or latent tuberculosis
  • Positive for , (HCV), or (HBV)
  • Known or suspected chronic active Epstein-Barr virus infection
  • Known or suspected history of hemaphagocytic lymphohistiocytosis (HLH)
  • Prior treatment with systemic immunotherapeutic agents
  • History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents
  • Documented refractoriness to an obinutuzumab monotherapy-containing regimen
  • Treatment with standard radiotherapy, any chemotherapeutic agent, including CAR T therapy
  • Prior solid organ or allogenic stem cell transplantation
  • stem cell transplantation within 100 days prior to obinutuzumab infusion
  • Active disease requiring treatment
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • Current or past history of CNS lymphoma
  • Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders, and known autoimmune diseases
  • Major surgery or significant traumatic injury \< 28 days prior to obinutuzumab infusion (excluding ) or anticipation of the need for major surgery during study treatment
  • Another invasive in the last 2 years
  • Significant cardiovascular disease
  • Administration of a live, attenuated vaccine within 4 weeks before obinutizumab infusion, or anticipation that one will be required during the study
  • Systemic immunosuppresive medications
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    R/R DLBCL

    Participants will receive a fixed dose of obinutuzumab pre-treatment followed by glofitamab on Cycle 1 Days 8 and 15, then every 3 weeks (Q3W) from Cycles 2-12 (cycle length = 21 days).

    Drug: Obinutuzumab · Drug: Glofitamab · Drug: Tocilizumab

Interventions

  • Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.

  • Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).

  • Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to 3.5 years

  2. Serum Concentration of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  3. Total Exposure (AUC) of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  4. Maximum Serum Concentration (Cmax) of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  5. Minimum Serum Concentration (Cmin) of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  6. Clearance of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  7. Volume of Distribution at Steady State (Vss) of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  8. Half-life (T1/2) of Glofitamab

    Time frame: At pre-defined intervals up to 3.5 years

  9. Complete Response Rate (CRR) as Assessed by an Independent Review Committee (IRC)

    Time frame: Up to 3.5 years

  10. Percentage of Participants with Anti-Drug Antibodies (ADA)

    Time frame: Up to 3.5 years

Secondary outcomes

  1. Investigator-Assessed CRR

    Time frame: Up to 3.5 years

  2. Objective Response Rate (ORR) as Assessed by IRC

    Time frame: Up to 3.5 years

  3. ORR as Assessed by Investigator

    Time frame: Up to 3.5 years

  4. Duration of Objective Response (DOR) as Assessed by IRC and Investigator

    Time frame: Up to 3.5 years

  5. Duration of Complete Response (CR) as Assessed by IRC and Investigator

    Time frame: Up to 3.5 years

  6. Progression-Free Survival (PFS) as Determined by IRC and Investigator

    Time frame: Up to 3.5 years

  7. Overall Survival (OS)

    Time frame: Up to 3.5 years

  8. Time to First Overall Response (TFOR) as Assessed by IRC and Investigator

    Time frame: Up to 3.5 years

  9. Time to First Complete Response (TFCR) as Assessed by IRC and Investigator

    Time frame: Up to 3.5 years

07

Study locations

6 sites
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology
    Guangzhou City, 510060, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Jiangsu Province Hospital
    Nanjing, 210008, China
  • Tianjin Cancer Hospital
    Tianjin, 300060, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Oct 2022, 21 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 21 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
Jan 8, 2021
Primary completionActual
Oct 25, 2022
CompletionActual
Jan 12, 2024
Last update
Jan 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04657302
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Jan 8, 2021
Primary completion
Oct 25, 2022
Completion
Jan 12, 2024
Last update
Jan 19, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glofitamab

Start the discussion